Food and oral antineoplastics: More than meets the eye

Clinical Cancer Research

Volumn 16, Issue 17, 2010, Pages 4305-4307

  Jain, Rajul K ^a   Brar, Satjit S ^b   Lesko, Lawrence J ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB;

AREA UNDER THE CURVE; AWARENESS; CALORIC INTAKE; DEATH; DIGESTIVE SYSTEM PERFORATION; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FOOD DRUG INTERACTION; FOOD PACKAGING; HUMAN; LIPID DIET; NOTE; PHYSICIAN; PRIORITY JOURNAL; SIDE EFFECT;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG LABELING; FASTING; FOOD; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; PHARMACEUTICAL PREPARATIONS;

EID: 77956233818     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1857     Document Type: Note

References (10)

1. Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res 2010;16:4446-51.
2. Lasswell AB, DeForge BR, Sobal J, Muncie HL, Jr., Michocki R. Family medicine residents' knowledge and attitudes about drug-nutrient interactions. J Am Coll Nutr 1995;14:137-43.
3. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006;6:546-58.
4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Rockville (MD): U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2002. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Available from: http://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070241.pdf.
5. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999;37:213-55.
6. Koch KM, Reddy NJ, Cohen RB, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009;27: 1191-6.
7. Rahman A, Pazdur R, Wang Y, Huang SM, Lesko L. The value meal: effect of food on lapatinib bioavailability. J Clin Oncol 2007;25:5333-4, author reply 4-5.
8. Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 2004;43: 1127-56.
9. Novartis Pharmaceuticals Corporation: East Hanover (NJ). Prescribing information gleevec (imatinib mesylate). May 2009. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/021588s026s028lbl.pdf.
10. Merck & Co., Inc.: Whitehouse Station (NJ). Prescribing information temodar (ternozolomide). April 2010. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/021029s018lbl.pdf.